Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
S Afr J Infect Dis ; 34(1): 129, 2019.
Article in English | MEDLINE | ID: mdl-34485459

ABSTRACT

BACKGROUND: Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) have been increasing worldwide in recent years, but data regarding the prevalence and clinical significance of CPE colonisation in South Africa is not well documented. Local private hospital groups have implemented routine screening programmes for selected high-risk patients as endorsed by the South African Society for Clinical Microbiology. This practice is not routinely performed in the public sector. METHODS: A point prevalence study was performed at Tygerberg Hospital (TBH) by screening patients of all the adult inpatient wards to investigate the current prevalence of CPE colonisation. Common risk factors associated with CPE colonisation were also investigated. RESULTS: From a total of 439 patient samples collected, only one patient was colonised with a Klebsiella pneumoniae organism harbouring blaNDM-1. The identified patient had none of the common risk factors associated with CPE colonisation. CONCLUSION: Based on these findings, screening for CPE colonisation in adults on admission to TBH is currently not recommended.

2.
Article in English | AIM (Africa) | ID: biblio-1270685

ABSTRACT

Escherichia coli is the most common cause of urinary tract infections. Knowledge of its local antimicrobial susceptibility patterns can be used to inform choice of empiric antimicrobial therapy. In this article; we review data on antimicrobial susceptibility patterns of E. coli isolated from unselected urine specimens; in both the private and public sectors of South Africa from 2007-2011. Between 65 000-84 000 E. coli urinary isolates were reported annually from 19 laboratories located across South Africa. Susceptibility to fluoroquinolone and beta-lactam antibiotics decreased significantly and steadily in both private and public sectors over the five-year period; although laboratory-based surveillance data may underestimate susceptibility rates due to selection bias and lack of differentiation between community- and hospital-acquired infections. Our data suggest that fluoroquinolones; co-amoxiclav and first- and second-generation cephalosporins can still be used for empiric treatment in many local settings; but clinicians should be alert to the risk of treatment failure. With the withdrawal of nitrofurantoin from the local market; other oral antibiotic options are limited; and fosfomcyin may become increasingly important. Given their sustained high susceptibility rates; aminoglycosides should be considered to treat pyelonephritis more often. Judicious use of laboratory testing is advised and further research and surveillance is warranted


Subject(s)
Anti-Infective Agents , Escherichia coli , Patients , Sensitivity and Specificity , Urinary Tract Infections
4.
Lancet ; 371(9618): 1108-13, 2008 Mar 29.
Article in English | MEDLINE | ID: mdl-18359074

ABSTRACT

BACKGROUND: Use of fluoroquinolones to treat paediatric cases of multidrug-resistant tuberculosis could affect the emergence of resistance to this class of drugs. Our aim was to estimate the incidence of, and risk factors for, invasive pneumococcal disease caused by fluoroquinolone-resistant Streptococcus pneumoniae in children in South Africa. METHODS: 21,521 cases of invasive pneumococcal disease were identified by active national surveillance between 2000 and 2006, with enhanced surveillance at 15 sentinel hospitals in seven provinces introduced in 2003. We screened 19,404 isolates (90% of cases) for ofloxacin resistance and measured levofloxacin minimum inhibitory concentrations (MICs) for all isolates that were ofloxacin resistant. Non-susceptibility to levofloxacin was defined as an MIC of 4 mg/L or more. Nasopharyngeal pneumococcal carriage was assessed in 65 children in two tuberculosis hospitals where invasive pneumococcal disease caused by levofloxacin-non-susceptible S pneumoniae had been detected. FINDINGS: 12 cases of invasive pneumococcal disease were identified as being non-susceptible to levofloxacin, all in children aged under 15 years. All isolates were rifampicin resistant. Outcome was known for 11 of these patients; five (45%) died. Invasive disease caused by levofloxacin-non-susceptible S pneumoniae was associated with a history of tuberculosis treatment (eight [89%] of nine children with non-susceptible isolates had a history of treatment vs 396 [18%] of 2202 children with susceptible isolates; relative risk [RR] 35.78, 95% CI 4.49-285.30) and nosocomial invasive pneumococcal disease (eight [80%] of ten children with non-susceptible isolates had acquired infection nosocomially vs 109 [4%] of 2709 with susceptible isolates; RR 88.96, 19.10-414.29). 31 (89%) of 35 pneumococcal carriers had bacteria that were non-susceptible to levofloxacin. INTERPRETATION: Our data suggest that the use of fluoroquinolones to treat multidrug-resistant tuberculosis in children has led to the emergence of invasive pneumococcal disease caused by levofloxacin-non-susceptible S pneumoniae and its nosocomial spread.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antitubercular Agents/therapeutic use , Drug Resistance, Bacterial/drug effects , Levofloxacin , Ofloxacin/therapeutic use , Pneumococcal Infections/drug therapy , Tuberculosis, Multidrug-Resistant/drug therapy , Adolescent , Child , Child, Preschool , Cross Infection , Cross-Sectional Studies , Female , Humans , Infant , Male , Pneumococcal Infections/epidemiology , Population Surveillance , Rifampin/therapeutic use , Risk Factors , South Africa/epidemiology , Statistics, Nonparametric , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/pathogenicity , World Health Organization
SELECTION OF CITATIONS
SEARCH DETAIL
...